Yu Mao

Yu Mao


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2017 in BMC Urology
Verified
Journal Article
Open access
PDF file
YMYu Mao
Yu Mao
SCShaoji Chen
Shaoji Chen
RWRu Wang
Ru Wang
XWXuejun Wang
Xuejun Wang
DQDaorui Qin
Daorui Qin
YMYu Mao
Yu Mao
The aim of this study is to review and present the clinical features and process of evaluation and treatment for OT-DSD in a single center in recent years in China. Sixteen patients with OT-DSD during the past 4 years underwent the evaluation and treatment in a single center. The clinical characteristics and outcomes of surgery were analyzed. The surgical age ranged from 17 months to 66 months with a mean age of 20 months, and the mean follow-up was 30 months (4 months to 56 months). The presentation in 11 patients was ambiguous genitalia, and the rest 5 patients were suspected to have DSD in preoperative examination before hypospadias repair. The karyotypes were 46, XX in 11 patients, 46, XX/46, XY in 3, 46, XX/47, XXY in 1, and 46, XY in 1. Initial reared sex was male in 14 patients, female in 1, and undetermined in 1. After surgery, genders were reassigned in 3 patients, while 15 patients were raised as male with testicular tissue left. Only 1 patient with ovarian tissue left was raised as female. Repair was completed in 11 males and 1 female, and stage I urethroplasty was done in 4 males. No further surgery to remove the gonads was needed for inconsonance of gender assignment. No gonadal tumors were detected. OT-DSD is a rare and complex deformity with few systematic reports in China. It’s important to establish a regular algorithm for evaluation and treatment of OT-DSD.

1 November 2022 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
ZHZirong He
Zirong He
BYBo Yang
Bo Yang
YTYunman Tang
Yunman Tang
YMYu Mao
Yu Mao
Original Article Analysis of factors associated with postoperative complications after primary hypospadias repair: a retrospective study Zirong He, Bo Yang, Yunman Tang, Yu Mao

9 November 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
SRShangqing Ren
Shangqing Ren
HWHan Wang
Han Wang
BYBo Yang
Bo Yang
YZYang Zheng
Yang Zheng
YOYong Ou
Yong Ou
YFYunlin Feng
Yunlin Feng
Objective: A novel albumin-to-alkaline phosphatase ratio (AAPR) is associated with the prognosis of several cancers. In the present study, we evaluate the prognostic significance of perioperative AAPR in urological cancers.Method: Relevant studies were searched comprehensively from CNKI, PubMed, Embase and Web of Science up to March 2023. The pooled hazard ratio (HR) and 95% confidence interval (CI) were extracted from each study to evaluate the prognostic value of perioperative AAPR in patients with surgically treated urological cancers.Results: A total of 8 studies consisting of 3,271 patients were included in the final results. A low AAPR was significantly associated with a worse OS (HR=2.21; P<0.001), CSS (HR=2.61; P<0.001) and RFS/DFS (HR=2.87; P=0.001). Stratified by disease, a low AAPR was also associated with worse OS in renal cell carcinoma (HR=2.01; P<0.001), bladder cancer (HR=3.37; P<0.001) and upper tract urothelial carcinoma (HR=1.59; P=0.002).Conclusion: In conclusion, low AAPR could serve as an unfavorable factor in patients with surgically treated urological cancers. Stratified by tumor type, the low AAPR was also associated with inferior survival. While more prospective and large-scale studies are warranted to validate our findings.

14 May 2021 in European Burn Journal
Verified
Journal Article
Open access
PDF file
RWRu Wang
Ru Wang
PDPatricia L. Danielsen
Patricia L. Danielsen
Magnus S. ÅgrenMagnus S. Ågren
Magnus S. Ågren
JDJanine Duke
Janine Duke
Fiona WoodFiona Wood
Fiona Wood
YCYing Cen
Ying Cen
Keloid scars are difficult to manage and remain a therapeutic challenge. Corticosteroid therapy alone or ionising radiation (radiotherapy) alone or combined with surgery are first-line treatments, but the scientific justification for these treatments is unclear. The aim of this systematic review and meta-analysis of randomised controlled trials (RCTs) is to assess the effects of intralesional corticosteroid injection in treating keloids or preventing their recurrence after surgical removal. Searches for RCTs were conducted through the MEDLINE, EMBASE, EBSCO and Cochrane databases from January 1974 to September 2017. Two authors independently reviewed study eligibility, extracted data, analysed the results, and assessed methodological quality. Sixteen RCTs that included more than 814 patients were scrutinised. The quality of evidence for most outcomes was moderate to high. In 10 RCTs, corticosteroid intralesional injections were compared with 5-fluorouracil, etanercept, cryosurgery, botulinum toxin, topical corticosteroid under a silicone dressing, and radiotherapy. Corticosteroid intralesional injections were more effective than radiotherapy (RR 3.3, 95% CI: 1.4–8.1) but equipotent with the other interventions. In conjunction with keloid excision, corticosteroid treatment was compared with radiotherapy, interferon α-2b and verapamil. In two RCTs, there were fewer keloid recurrences (RR 0.43, 95% CI: 0.21–0.89) demonstrated with adjuvant radiotherapy than with corticosteroid injections. More high-quality, large-scale RCTs are required to establish the effectiveness of corticosteroids and other therapies in keloid management.

29 July 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
GWGuopeng Wang
Guopeng Wang
XDXiang Dong
Xiang Dong
XZXintong Zhang
Xintong Zhang
CGChengpeng Gu
Chengpeng Gu
THTing Hu
Ting Hu
SRShangqing Ren
Shangqing Ren
Background: Risk stratification remains challenging in patients with upper tract urothelial carcinoma (UTUC) undergoing radical nephroureterectomy (RNU). Preoperative systemic inflammatory biomarkers may provide prognostic information, but their relative clinical utility remains unclear. Methods: This systematic review and meta-analysis evaluated five commonly used preoperative inflammatory biomarkers—neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI)—in patients with UTUC treated with RNU. PubMed, Embase, Web of Science, and Cochrane Library were searched up to March 2026. Multivariate hazard ratios (HRs) for overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) were pooled using random-effects models. Evidence certainty was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Results: Twelve retrospective studies comprising 7,346 patients were included. Elevated inflammatory biomarker levels were generally associated with worse survival outcomes across available studies. Significant associations with overall survival were observed for SIRI (pooled HR 2.09, 95% CI 1.27–3.44), NLR (pooled HR 1.97, 95% CI 1.74–2.22, I²=14.1%), MLR, SII, and PLR; comparable associations were seen for cancer-specific and recurrence-free survival. Each biomarker was analysed in a separate meta-analysis, and the contributing studies differed in design, populations, and cut-off values; the markers were therefore not compared statistically, and no inference regarding their relative prognostic performance is made. Conclusion: Preoperative systemic inflammatory biomarkers are individually associated with oncological outcomes following RNU for UTUC. Because each marker was pooled separately and the studies were clinically heterogeneous, the markers were not compared statistically and no ranking is implied; the findings are descriptive and hypothesis-generating. This meta-analysis of aggregate data did not assess predictive performance (discrimination, calibration, or clinical utility), and any SIRI–NLR combination remains a hypothesis requiring prospective, individual-patient-data validation before any clinical application. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261307425 , identifier CRD420261307425.

9 October 2026 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GWGuopeng Wang
Guopeng Wang
XDXiang Dong
Xiang Dong
XZXintong Zhang
Xintong Zhang
CGChengpeng Gu
Chengpeng Gu
THTing Hu
Ting Hu
SRShangqing Ren
Shangqing Ren
Preoperative staging of upper tract urothelial carcinoma (UTUC) relies on cross-sectional imaging and ureteroscopic biopsy, both with recognised limitation